Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 1/20 | 0.47 |
| ▸ | BCHE | P06276 | 4/20 | 0.40 |
| ▸ | BACE1 | P56817 | 3/20 | 0.40 |
| ▸ | HTR2A | P28223 | 2/20 | 0.40 |
| ▸ | HTR2B | P41595 | 2/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.40 |
| ▸ | CCR9 | P51686 | 1/20 | 0.38 |
| ▸ | TACR1 | P25103 | 2/20 | 0.37 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.37 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.36 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.36 |
| ▸ | MIF | P14174 | 1/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.36 |
| ▸ | KIF11 | P52732 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5753904 | 0.88 | SLC2A1 (0.43) | PNMTSLC2A1AOC3ADRB1 | |
| SCHEMBL5752090 | 0.81 | CCR9 (0.43) | PNMTBCHEBACE1CCR9ADRB1 | |
| SCHEMBL5754070 | 0.81 | SLC2A1 (0.43) | PNMTSLC2A1AOC3ADRB1ADRA1A | |
| SCHEMBL5750724 | 0.80 | SLC2A1 (0.40) | PNMTSLC2A1AOC3ADRB1ADRA1A | |
| SCHEMBL5752386 | 0.80 | PNMT (0.42) | PNMTTACR1SLC2A1ADRB1 | |
| SCHEMBL5753866 | 0.79 | SLC2A1 (0.42) | PNMTSLC2A1AOC3ADRB1ADRA1A | |
| SCHEMBL5752334 | 0.78 | SLC2A1 (0.46) | SLC2A1ADRB1ADRA1A | |
| SCHEMBL5750415 | 0.75 | CETP (0.44) | — | |
| SCHEMBL5750636 | 0.74 | HTR2A (0.47) | PNMTBACE1HTR2AHTR2BHTR2C | |
| SCHEMBL5751392 | 0.73 | SLC2A1 (0.39) | PNMTTACR1SLC2A1AOC3ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6982348-B2 | Aminoethanol derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-01-03 | — | — | US | disclosed |
| US-20040127574-A1 | Aminoethanol derivatives | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-07-01 | — | — | US | disclosed |
| EP-1362846-A1 | AMINOETHANOL DERIVATIVES | Takeda Chemical Industries, Ltd. (JP) | 2003-11-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040127574-A1 | Aminoethanol derivatives | CETP, LCAT, MTTP | PNMT 172/4885BCHE 334/4885BACE1 835/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.